Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Multiple Myeloma and Smoldering Myeloma: Prospective Evaluation of 3 T Whole Body MRI and 18F-FDG PET/CT and Their Impact on Clinical Management

Claudio Cerchione, Davide Bezzi, Davide Nappi, Matteo Marchesini, Andrea Prochowski Iamurri, Paola Caroli, Arrigo Cattabriga, Delia Cangini, Giacomo Feliciani, Emiliano Loi, Federica Matteucci, Domenico Barone, Sonia Ronconi, Michela Ceccolini, Gerardo Musuraca, Nicola Normanno, Giovanni Martinelli, Alice Rossi

Blood (2024) 144 (Supplement 1): 3326.

https://doi.org/10.1182/blood-2024-211380

Published: 2024

Journal Articles

Radiopsy, Quantitative Wb-Mri Adc and Fat Fraction Sequences for Discrimination of Smoldering Multiple Myeloma and Multiple Myeloma: A Prospective Observational Study

Claudio Cerchione, Alice Rossi, Paola Caroli, Matteo Marchesini, Federica Matteucci, Delia Cangini, Domenico Barone, Davide Nappi, Davide Bezzi, Anna Sarnelli, Giovanni Martinelli, Nicola Normanno, Giacomo Feliciani

Blood (2024) 144 (Supplement 1): 4725.

https://doi.org/10.1182/blood-2024-210734

Published: 2024

Journal Articles

Characterizing Thrombotic Risk in TEMPI Syndrome: A Retrospective Case Series

Graham Blake Parker, Justin Cheng, Louis Terriou, Johanna Strobl, Ayesha Iftikhar, Davide Nappi, Meng Pan, Pierre-Yves Sansen, Elisa Diral, Elena Maria Elli, Wilfried A Schroyens, David B. Sykes, Casey L. O'Connell, Caitlin M O'Neill

Blood (2024) 144 (Supplement 1): 5551.

https://doi.org/10.1182/blood-2024-199861

Published: 2024

Journal Articles

Combining Gene Expression Profiling and Integrated Multidisciplinary Approaches to Improve Prognosis Prediction in Multiple Myeloma

Claudio Cerchione, Nour Alassi, Davide Nappi, Chiara Servili, Emanuela Scarpi, Delia Cangini, Sonia Ronconi, Michela Ceccolini, Matteo Paganelli, Luigi Coppola, Giacomo Feliciani, Alice Rossi, Fabiana Mammoli, Nicola Normanno, Gerardo Musuraca, Giorgia Simonetti, Giovanni Martinelli, Matteo Marchesini

Blood (2024) 144 (Supplement 1): 6838.

https://doi.org/10.1182/blood-2024-203211

Published: 2024

Journal Articles

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Agnese Mattei, Giovanni Marconi, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Claudio Cerchione, Irene Zacheo, Maria Benedetta Giannini, Marianna Norata, Giovanni Martinelli, Anna Ferrari, Maria Teresa Bochicchio, Martina Ghetti, Matteo Marchesini, Giorgia Simonetti, Gerardo Musuraca, Davide Nappi

Blood (2023) 142 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2023-186760

Published: 2023

Journal Articles

Safety and Efficacy of New Drugs Combinations in Newly Diagnosed Multiple Myeloma with Renal Failure at Onset: A Retrospective Multicentric Study

Antonio Frolli, Claudio Cerchione, Riccardo Staiano, Tommasina Guglielmelli, Davide Nappi, Agnese Mattei, Silvia Marini, Daniela Cilloni, Guido Eugenio Parvis

Blood (2023) 142 (Supplement 1): 6656.

https://doi.org/10.1182/blood-2023-190212

Published: 2023

Journal Articles

Chemo or Chemo-Free Regimens in Heavily Pretreated Multiple Myeloma? Role of Bendamustine-Bortezomib-Dexamethasone (BVD) in NOVEL Agents' Era

Claudio Cerchione, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, Sonia Ronconi, Michela Ceccolini, Giovanni Martinelli, Fabrizio Pane

Blood (2022) 140 (Supplement 1): 12585–12586.

https://doi.org/10.1182/blood-2022-170484

Published: 2022

Journal Articles

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Claudio Cerchione, Davide Nappi, Gerardo Musuraca, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Giovanni Martinelli

Blood (2022) 140 (Supplement 1): 13248–13249.

https://doi.org/10.1182/blood-2022-170561

Published: 2022

Journal Articles

Role of Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Claudio Cerchione, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Fabrizio Pane, Giovanni Martinelli

Blood (2021) 138 (Supplement 1): 4760.

https://doi.org/10.1182/blood-2021-153877

Published: 2021

Journal Articles

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Claudio Cerchione, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Fabrizio Pane, Giovanni Martinelli

Blood (2021) 138 (Supplement 1): 5022.

https://doi.org/10.1182/blood-2021-153971

Published: 2021

Journal Articles

Bendamustine-Bortezomib-Dexamethasone in Heavily Pretreated Multiple Myeloma: Old PLUS New Drugs in NOVEL Agents' Era

Claudio Cerchione, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Fabrizio Pane, Giovanni Martinelli

Blood (2021) 138 (Supplement 1): 5021.

https://doi.org/10.1182/blood-2021-153954

Published: 2021

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma

Claudio Cerchione, Davide Nappi, Anna Emanuele Pareto, Fabrizio Pane, Lucio Catalano, Giovanni Martinelli

Blood (2021) 138 (Supplement 1): 5020.

https://doi.org/10.1182/blood-2021-153933

Published: 2021

Journal Articles

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Claudio Cerchione, MD PhD, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, MD, Alessandro Lucchesi, MD, Fabrizio Pane, Giovanni Martinelli, MD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-143178

Published: 2020

Journal Articles

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Claudio Cerchione, MD PhD, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, MD, Alessandro Lucchesi, MD, Sonia Ronconi, Michela Ceccolini, MD, Delia Cangini, Maria Benedetta Giannini, MD, Valeria Di Battista, Giorgia Simonetti, PhD, Andrea Ghelli Luserna Di Rorà, PhD, Fabrizio Pane, Giovanni Martinelli, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143143

Published: 2020

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma

Claudio Cerchione, MD PhD, Lucio Catalano, Davide Nappi, Gerardo Musuraca, MD, Alessandro Lucchesi, MD, Fabrizio Pane, Giovanni Martinelli, MD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-143189

Published: 2020

Journal Articles

Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in NOVEL Agents' Era

Claudio Cerchione, MD PhD, Lucio Catalano, Davide Nappi, Stefano Rocco, Salvatore Palmieri, Anna Emanuele Pareto, Gerardo Musuraca, MD, Alessandro Lucchesi, MD, Fabrizio Pane, Felicetto Ferrara, MD, Giovanni Martinelli, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-143207

Published: 2020

Journal Articles

ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study

Patrizia Mondello, MD PhD MSc, Irene Dogliotti, MD, Jan-Paul Bohn, Federica Cavallo, Simone Ferrero, MD, Barbara Botto, Claudio Cerchione, MD PhD, Davide Nappi, Sonya De Lorenzo, Giovanni Martinelli, MD, Dominik Wolf, Univ. Prof. Dr., Giacomo Loseto, MD, Salvatore Cuzzocrea, MD PhD, Wolfgang Willenbacher, MD PhD, Michael Mian, MD

Blood (2019) 134 (Supplement_1): 1565.

https://doi.org/10.1182/blood-2019-128198

Published: 2019

Journal Articles

Adding Hydroxyurea in Combination with Ruxolitinib Improves Clinical Responses in Hyperproliferative Forms of Myelofibrosis

Novella Pugliese, MD, Claudia Giordano, MD, Davide Nappi, Luigia Luciano, MD, Claudio Cerchione, MD PhD, Mario Annunziata, Beniamino Casale, Elena Crisà, MD, Maria Rosaria Villa, Luca Pezzullo, Mariolina Iovine, Marco Picardi, MD, Francesco Grimaldi, MD, Maria Monteverde, Fabrizio Pane

Blood (2018) 132 (Supplement 1): 4290.

https://doi.org/10.1182/blood-2018-99-118986

Published: 2018

Journal Articles

Pegfilgrastim Versus Filgrastim in the Management of Therapy-Related Neutropenia in Relapsed and Refractory Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Claudio Cerchione, MD PhD, Davide Nappi, Fabrizio Pane, Lucio Catalano

Blood (2018) 132 (Supplement 1): 5905.

https://doi.org/10.1182/blood-2018-99-119972

Published: 2018

Journal Articles

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Claudio Cerchione, MD PhD, Davide Nappi, Anna Emanuele Pareto, Fabrizio Pane, Lucio Catalano

Blood (2018) 132 (Supplement 1): 5648.

https://doi.org/10.1182/blood-2018-99-119991

Published: 2018

NARROW

Multiple Myeloma and Smoldering Myeloma: Prospective Evaluation of 3 T Whole Body MRI and 18F-FDG PET/CT and Their Impact on Clinical Management

Radiopsy, Quantitative Wb-Mri Adc and Fat Fraction Sequences for Discrimination of Smoldering Multiple Myeloma and Multiple Myeloma: A Prospective Observational Study

Characterizing Thrombotic Risk in TEMPI Syndrome: A Retrospective Case Series

Combining Gene Expression Profiling and Integrated Multidisciplinary Approaches to Improve Prognosis Prediction in Multiple Myeloma

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Safety and Efficacy of New Drugs Combinations in Newly Diagnosed Multiple Myeloma with Renal Failure at Onset: A Retrospective Multicentric Study

Chemo or Chemo-Free Regimens in Heavily Pretreated Multiple Myeloma? Role of Bendamustine-Bortezomib-Dexamethasone (BVD) in NOVEL Agents' Era

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Role of Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Bendamustine-Bortezomib-Dexamethasone in Heavily Pretreated Multiple Myeloma: Old PLUS New Drugs in NOVEL Agents' Era

Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma

Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in NOVEL Agents' Era

ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study

Adding Hydroxyurea in Combination with Ruxolitinib Improves Clinical Responses in Hyperproliferative Forms of Myelofibrosis

Pegfilgrastim Versus Filgrastim in the Management of Therapy-Related Neutropenia in Relapsed and Refractory Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only